arrow
A

Alena Gros

vall d'hebron institute of oncology
H指数:34
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

作者更正:化疗的疗效受限于表达PD-L2的肿瘤内衰老细胞

2026-05-290
OAAI
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis

使用肿瘤浸润淋巴细胞联合高剂量重组白细胞介素2进行过继治疗在晚期皮肤黑色素瘤中的安全性:一项系统评价和Meta分析

2025-04-080
PRE
Syndecan-3 positively regulates the pro-inflammatory function of macrophages

Syndecan-3 正向调控巨噬细胞的促炎功能。

2025-04-070
OA
Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors

液体活检追踪免疫疗法诱导的T细胞动态变化在微卫星稳定性结直肠癌和子宫内膜肿瘤中的作用

2024-09-010
PRE
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study
2024-08-120
PRE
The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

表达PD-L2的肿瘤内衰老细胞限制了化疗的功效

2024-01-2424
OAAI
An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)

研究者启动的I期研究,以评估体外下一代新抗原选择的肿瘤浸润淋巴细胞 (TIL) 疗法在晚期免疫检查点阻断 (ICB) 耐药实体瘤中的安全性和耐受性 (nextgentil-act)

2023-10-010
PRE
MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC)
2023-06-011
OA
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

新抗原靶向CD8 T细胞反应与PD-1阻断治疗

Nature
IF48.5
2023-03-080
PRE
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.

肿瘤反应性CD4和CD8 til的生物标志物与子宫内膜癌预后改善相关。

2022-12-2922
OAAI
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

细胞衰老具有免疫原性并促进抗肿瘤免疫

2022-10-27133
OAAI
MONEO: A phase II study of avelumab plus FLOT in the perioperative treatment for patients with resectable gastric or gastroesophageal junction cancer
2021-07-010
OAAI